In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

This also marks the second signification project for Johnson & Johnson in Wilson, as back in October 2024, the company ...

The executive spoke at the 44 th annual 2026 JP Morgan Healthcare Conference in San Francisco early on Monday, January 12.

Michael O' Rurke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its ...

Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while ...

PE: How can teams reduce patient burden without weakening their science? Schwab: Number one is lean trial design. We should ...

Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while navigating fragmented data systems, access hurdles, and prior authorization demands ...

32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...

Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America ...

Johnson & Johnson continues its $55 billion investment in U.S. operations (first announced back in 2025), targeting ...